RESET-SLE Trial
Phase 1/2
28
about 5.9 years
18–65
21 sites in CA, CT, FL +10
What this study is about
Researchers are testing the safety and effectiveness of a new treatment called CABA-201 for people with active lupus nephritis or systemic lupus erythematosus. The trial will evaluate different doses of this treatment in patients who have not been treated with cyclophosphamide and fludarabine.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CABA-201
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To evaluate incidence of adverse events
Secondary: To characterize the pharmacodynamics (PD), To characterize the pharmacokinetics (PK), To evaluate adverse events and laboratory abnormalities
Immune